
Conference Coverage
about 11 hours ago
Patient Fit Matters Most When Choosing the Right COPD Inhalerabout 11 hours ago
COPD Disease Stability Emerges as a Treatment Target in GOLD 2026about 18 hours ago
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatmentabout 19 hours ago
Anti-Alarmin Therapy in COPD Exacerbations: Jadwiga A. Wedzicha, MDabout 20 hours ago
2027 GOLD COPD Report Updates: Àlvar Agustí, MD, PhDabout 22 hours ago
Unmet Goals Should Prompt COPD Support Review: Gerard Criner, MDabout 22 hours ago
National Risk Pool Would Spread Cell, Gene Therapy Costs Across PayersLatest Content

Patient Fit Matters Most When Choosing the Right COPD Inhaler

COPD Disease Stability Emerges as a Treatment Target in GOLD 2026

CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region

EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules

How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment

Shorts










Center on Health Equity & Access
All News

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.

Pooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.

Among 788 patch-tested patients with hand eczema in Shanghai, 82% reacted to at least 1 allergen.

The Community Oncology Alliance said final 2027 Medicare payment rules address longstanding gaps between hospital and community practice reimbursement, but it urged Congress to stop another physician pay cut and to fix how the Inflation Reduction Act will pay practices for Part B drugs.

Gerald Criner, MD, outlines which patients with advanced COPD may need oxygen, home NIV, or high-flow therapy and when to discuss goals of care.

The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.

In 299 patients, more involved compartments were linked to higher complication risk after one-stage resection; 14.4% had documented recurrence.

A cranberry supplement was tied to greater OAB symptom score reductions than placebo in a 25-woman pilot trial, but urobiome findings were unconfirmed.

In a matched analysis of Epic COSMOS records, acoramidis was tied to an 18% lower composite risk and about 25% lower hospitalization risk.

A runner's death at the NYC marathon highlights how heat, dehydration, illness, drugs, and genetics can raise exertional rhabdomyolysis risk.




























